News | September 20, 2011

Study Shows Fluid Monitoring in HF Patients Leads to Increased Hospital Visits


September 20, 2011 – A recent study sought to determine if monitoring fluid build-up in the chest of heart failure patients would lead to earlier detection of problems and prevent repeat hospitalizations. The results, released as part of the late-breaking trials at the 15th annual scientific meeting of the Heart Failure Society of America (HFSA), actually showed an increase in hospital visits.

D.J. van Veldhuisen, M.D., UMC Groningen, the Netherlands, presented the results.

Fluid builds up in the heart, which is unable to manage the increase in fluid. This results in patients requiring a hospital stay to correct the issue. The problem can cause weight gain, fatigue and shortness of breath.

The study focused on strategies for early detection of fluid overflow in order to avoid lengthy and costly hospital stays. Doctors studied 350 patients who had implantable cardioverter defibrillators (ICDs) with or without cardiac resynchronization; they were fitted with diagnostic systems to monitor intrathoracic impedance, which reflects fluid in the chest, a sign of (impeding) decompensation.

The systems are designed to emit a beep when fluid levels reach a certain threshold, signaling the patient to contact their doctor.

Doctors sought to determine if these systems would provide detection early enough to prevent the need for later hospitalization. The patients who were fitted with active diagnostic systems actually saw an increase in hospital visits, rather than the decrease doctors had hoped for.

As van Veldhuisen points out, patients may have become nervous about the alarm going off, which resulted in visits to the hospital rather than a phone call to their doctor. He also notes the human body naturally fluctuates from day to day, so the question becomes how quickly should doctors respond to slight changes

"Early detection of fluid buildup is the key to reducing hospital stays and improving quality of life for patients," van Veldhuisen said. "This study, among others, is aimed at finding the best ways to identify problems early, and monitoring patients remotely seems to be the best option. The question becomes which method we should use to monitor patients."

For more information: www.abouthf.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now